Previous Article | Next Article 
Journal of Virology, November 2001, p. 10912-10922, Vol. 75, No. 22
0022-538X/01/$04.00+0 DOI: 10.1128/JVI.75.22.10912-10922.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Neuroadapted Yellow Fever Virus 17D: Genetic and Biological
Characterization of a Highly Mouse-Neurovirulent Virus and Its
Infectious Molecular Clone
Thomas J.
Chambers* and
Michael
Nickells
Department of Molecular Microbiology and
Immunology, St. Louis University Health Sciences Center, St. Louis,
Missouri 63104
Received 22 May 2001/Accepted 16 August 2001
 |
ABSTRACT |
A neuroadapted strain of yellow fever virus (YFV) 17D derived
from a multiply mouse brain-passaged virus (Porterfield
YF17D) was additionally passaged in SCID and normal mice. The virulence properties of this virus (SPYF) could be distinguished from
nonneuroadapted virus (YF5.2iv, 17D infectious clone) by decreased
average survival time in SCID mice after peripheral inoculation,
decreased average survival time in normal adult mice after
intracerebral inoculation, and occurrence of neuroinvasiveness in
normal mice. SPYF exhibited more efficient growth in peripheral tissues
of SCID mice than YF5.2iv, resulting in a more rapid accumulation of
virus burden, but with low-titer viremia, at the time of fatal
encephalitis. In cell culture, SPYF was less efficient in replication
than YF5.2iv in all cell lines tested. The complete nucleotide sequence
of SPYF revealed 29 nucleotide substitutions relative to YF5.2iv, and
these were distributed throughout the genome. There were a total of 13 predicted amino acid substitutions, some of which correspond to known
differences among the Asibi, French viscerotropic virus, French
neurotropic vaccine, and YF17D vaccine strains. The envelope (E)
protein contained five substitutions, within all three functional
domains. Substitutions were also present in regions encoding the NS1,
NS2A, NS4A, and NS5 proteins and in the 3' untranslated region (UTR).
Construction of YFV harboring all of the identified coding nucleotide
substitutions and those in the 3' UTR yielded a virus whose cell
culture and pathogenic properties, particularly neurovirulence and
neuroinvasiveness for SCID mice, generally resembled those of the
original SPYF isolate. These findings implicate the E protein and
possibly other regions of the genome as virulence determinants during
pathogenesis of neuroadapted YF17D virus in mice. The determinants
affect replication efficiency in both neural and extraneural tissues of
the mouse and confer some limited host-range differences in cultured
cells of nonmurine origin.
 |
INTRODUCTION |
Viruses within the Flavivirus
genus of the family Flaviviridae are generally neurotropic,
exhibiting various degrees of neurovirulence in rodent and primate
hosts (41). Introduction of virus into the murine central
nervous system (CNS) causes an acute encephalitis, the outcome of which
can be influenced by the dose of virus and the age and strain of the
mouse (15). Different strains of yellow fever virus (YFV)
can be distinguished by their level of mouse neurovirulence (5,
15, 28, 52-54), and this property can be enhanced by serial
passage of the virus in mouse brain (37, 56, 59). This
neuroadaptation has also been observed with other flaviviruses
(7, 11, 25). Genetic analyses of viruses which differ in
their virulence properties have commonly focused on the envelope (E)
protein, for which a variety of mutations have been shown to modulate
neurovirulence (reviewed in reference 36). Regarding YFV,
nucleotide sequence analysis of the partially attenuated French
neurotropic virus (FNV) strain of YFV which was derived by mouse brain
passage of the wild French viscerotropic virus (FVV) strain, revealed
that numerous residues within the E protein, as well as in other
regions of the genome, were retained relative to the fully attenuated
17D vaccine (22, 61). FNV caused encephalitis in humans at
a rate higher than that which occurs with the YF17D vaccine strain
(16), and although the pathophysiologic mechanisms for
this phenomenon are not known, mutations in the E protein are presumed
to be important. A rare neurovirulent revertant of the YF17D vaccine
was shown to contain novel mutations only within the E protein
(23). The role of these various mutations in altering
those functional properties of the flavivirus E protein which increase
neurovirulence is not well understood. It is assumed that receptor
binding and subsequent events associated with virus entry, including
low-pH-induced conformational changes and fusion with intracellular
membranes, are principally involved (6, 32, 34, 35, 45, 46, 52,
54). In contrast to the E protein, neurovirulence determinants
in the nonstructural and untranslated regions have been less well
studied (8, 14, 25, 31, 38, 43, 47). These are likely to be important in relationship to host factors that affect enzymatic activities associated with viral transcription, translation of the
viral polyprotein, or virion assembly or to RNA structures involved in
cis-acting regulatory events and/or interactions with host proteins.
In a previous study, the mouse neurovirulence of a neuroadapted strain
of YF17D (Porterfield 17D) was initially characterized, and a
partial nucleotide sequence including the prM-through-NS2A region was
reported (55). This virus causes uniform mortality in young adult mice after intracerebral (i.c.) inoculation of as little
as 1 PFU of virus, replicates in mouse brain tissue more rapidly than
nonneuroadapted virus, and results in higher peak titers of
brain-associated virus and earlier death. Mutations at five positions
in the E protein, as well as single substitutions in the NS1 and NS2A
proteins, were identified in that study. However, the importance of
these substitutions for the mouse-neurovirulent phenotype could not be
demonstrated. To further investigate the genetic basis of the enhanced
virulence of neuroadapted YF17D virus, we determined the complete
nucleotide sequence of a plaque-purified virus (SPYF) after
characterization of its virulence properties in mice. We then
determined the phenotype of a corresponding virus engineered from cDNA
to contain the predicted amino acid substitutions specific to the SPYF
strain. In this investigation, adult SCID mice were found to be very
sensitive to differences in virulence between neuroadapted and
nonneuroadapted virus, developing a fatal encephalitis as early as 8 days after intraperitoneal (i.p.) inoculation of the SPYF strain. This
model offers the chance to investigate the virus-host interactions
which lead to neuroinvasion in the absence of virus-specific immunity.
Use of this model to understand the molecular basis for flavivirus
neurovirulence might therefore have implications for engineering live
attenuated viral vaccines based on recombinant DNA technology. For
instance, a nominal requirement for such vaccines is an acceptable
attenuation phenotype based on multiple stable genetic determinants
within the viral genome.
 |
MATERIALS AND METHODS |
Cells and viruses.
SW-13, BHK-21, Vero, and C6/36 cells were
used as previously described (10). The neuroadapted PYF
virus, which has undergone more than 20 passages in suckling mouse
brain, has been previously described (55). YF5.2iv virus
generated from a YF17D molecular clone has been previously described
(51). Plaque assays for virus quantitation were routinely
done in Vero cells, since the plaquing efficiency of the PYF virus in
SW-13 cells is poor. Viruses were diluted in phosphate-buffered saline
(PBS) plus 10% fetal bovine serum for injection into mice.
Mouse experiments.
Mice used in these experiments included
the ICR strain (Harlan/Sprague-Dawley and Taconic Farms), the SCID/ICR
strain (Taconic Farms), and the SCID C.B.-17 strain (Taconic Farms).
Mice were used between 3 and 6 weeks of age for studies of
neurovirulence. Mice were inoculated by the i.p. route for peripheral
inoculation or by the i.c. route, after anesthetization. Mice were
observed until the onset of a moribund condition and then sacrificed.
Statistical analyses of differences in mortality were done using
Fisher's exact test. Differences in survival times were analyzed using Wilcoxon rank-sum tests. For analysis of virus in tissues of infected mice, tissues were recovered by dissection after perfusion with PBS and
stored at
70°C until used for virus quantitation. Titration of
tissue-associated virus was done by preparing 20% suspensions of
tissue homogenates in a Dounce homogenizer in PBS plus 10% fetal
bovine serum and then performing plaque assays on Vero cells. The
plaque assay was done using serial dilutions of virus plated on cell
monolayers under 1.0% ME agarose (SeaKem) in alpha-minimum essential
medium plus 5% fetal bovine serum. Plaques were visualized by
staining after 5 days with 0.05% neutral red in PBS and then were
counted after fixation in 10% formalin and staining with crystal violet.
Derivation of SPYF.
The original Porterfield YF17D strain
(55) was used as the starting material. This virus was
inoculated at a dose of approximately one million PFU into 5-week-old
SCID mice (C.B.-17 strain) by the i.p. route, with onset of
encephalitis occurring between 2 and 3 weeks postinoculation. Virus was
obtained from the brain of a moribund mouse and a 20% brain suspension
was prepared for plaque titration and further passage. After a second
round of i.p. inoculation into SCID mice, the brain-associated virus
was subjected to three rounds of plaque purification in SW-13 cells, in
conjunction with amplification on BHK cells. Media from the third
rounds of plaque purifications and amplifications were inoculated into
3-week-old ICR mice by i.c. inoculation, and brains were harvested at
the onset of a moribund condition. One of these brain harvests was
passaged a final time on Vero cells to provide a working stock of
virus, hereafter referred to as SPYF. The nonneuroadapted YF5.2iv virus
was derived by transfection of SW-13 cells with SP6 transcripts from a
full-length in vitro-ligated cDNA template (51). The
progeny virus was plaque purified twice in SW-13 cells, amplified in
BHK cells, and passaged once on Vero cells to provide a working virus
stock with a passage history which matched that of the SPYF virus,
except for the mouse passages.
Molecular cloning and nucleotide sequencing.
RNA was
prepared from virus-infected SCID mouse brain at the onset of a
moribund condition after i.p. inoculation with the working stock of
SPYF virus. RNA was extracted using TRIzol (Life Technologies). The
oligonucleotide primers used for reverse transcription-PCR were as
follows: minus-strand primers, 10836-10861 (3'-GGAAACCTACTGTTTGTGTTTTGGTGA-5'), 9051-9074 (3'-CGGCACGGTATACCATATACACCG-5'), 6947-6965 (3'-GGTAGATCACGAAGTGGGA-5'), 5228-5250 (3'-GCGAACGCGTGAGAACACAACCG-5'), 2486-2503 (3'-CTCGAGTTCACGCCTCTA-5'), 773-788 (3'-TTGGTACCAAACTTCT-5'); and plus-strand primers, 1-22 (5'-AGTAAATCCTGTGTGCTAATTG-3'), 424-440 (5'-CCATGATGTTCTGACTG-3'), 2482-2503 (5'-GAGAGAGCTCAAGTGCGGAGAT-3'), 4803-4819 (5'-TTGTCGCCTATGGTGGC-3'), 6954-6975 (5'-GTGCTTCACCCTGGAGTTGGCC-3'), 9051-9073 (5'-GCCGTGCCATATGGTATATGTGG-3').
RNA was reverse transcribed using Superscript-RT (Gibco/BRL) and the
YF17D-specific minus-strand primers. The cDNA products were subjected
to PCR using Deep Vent DNA polymerase (New England Biolabs) and typical
amplification cycles of 2 min of denaturation, 1 min of annealing
(55°C), and extension for up to 2.5 min. PCR products were isolated
by agarose gel electrophoresis, purified using Wizard PCR preps
(Promega), and cloned into Zeroblunt-TOPO plasmids (Invitrogen). At
least duplicate reactions were cloned for each sample. Clones
containing correctly sized inserts were used for nucleotide sequencing.
Nucleotide sequencing was done using Big Dye chain terminator reactions
and was analyzed on an Applied Biosystems DNA sequencer. Chromatograms
were read manually for detection and verification of all nucleotide substitutions.
Reconstruction of virus.
A molecular clone of the SPYF
virus, hereafter referred to as SPYF-MN, was constructed as follows.
Construction of YFV plasmids pYF5'3'IV and pYFM5.2 harboring the SPYF
substitutions was done using standard cloning techniques to exchange
regions from the Zeroblunt-TOPO plasmids into either of these two
plasmids. pYF5'3'IV contains YFV nucleotides (nt) 1 to 2271 and 8275 to
10862 (YFV numbering) downstream of an SP6 promoter. pYFM5.2 contains
the YFV sequence from nt 1363 to 8704. Construction of pYF5'3'IV(SPYF) was done by incorporation of the SPYF sequence of nt 536 to 1655 and
9058 to 10708 in five steps. An AvaI/NsiI
fragment (containing SPYF nt 536 to 1655) was ligated into
pYF5'3'(del)-XhoI/SalI, from which an
XhoI/SalI fragment (nt 9423 to 10861) had been
excised. The deleted XhoI/SalI fragment was then
replaced with a NotI/NsiI fragment (nt 6675v to
1655) from pYF5'3'IV (where 6675v identifies the nucleotide position
within the vector portion of the plasmid). An
NdeI/XbaI fragment containing the SPYF sequence
from nt 9058 to 10708 was ligated into pYF5'3'IV(del)-BsmI,
from which a BsmI fragment (nt 459 to 1514) had been
deleted. The deleted BsmI fragment was then replaced with a
NotI/EcoRI fragment (nt 6675v to 2271) from
pYF5'3'IV. The EcoRI site in YF5'3'IV lies at the junction of YFV nt 2271 and 8275. The NotI/EcoRI fragment
from the plasmid containing the SPYF sequence from nt 536 to 1655 was
then ligated to the nt 2271-to-6675v NotI/EcoRI
fragment from the plasmid harboring the SPYF sequence from nt 9058 to
10708 to generate the final plasmid pYF5'3'IV(SPYF).
Construction of pYFM5.2(SPYF) required eight steps. The
NsiI/
SacI fragment containing SPYF nt 1655 to
2486 was ligated into
pYFM5.2(del)-
SacI, from which two
SacI fragments (from nt 2486
to 5108) had been excised. The
deleted
SacI fragments were then
replaced with a partial
SacI digestion product containing SPYF
nt 2486 to 5108. An
NheI/
AvaI fragment containing SPYF nt 5459
to
6797 was separately ligated into pYFM5.2(del)-
SacI and the
SacI deletion was restored with the partial
SacI
digestion fragment
from pYFM5.2. In a third construct pYFM5.2 was
digested with
SphI
and religated to excise the 1684-to-6897
SphI fragment and to
produce pYFM5.2(del)-
SphI,
and the
BsgI/
EcoRV fragment containing
SPYF nt
7444 to 8027 was ligated into this plasmid. A fourth plasmid
was
produced by partial digestion of pYFM5.2 with
BanII to
generate
pYFM(del)-partial
BanII lacking the YFV sequence
between nt 1599
and 6330. Into this plasmid an
SphI/
XbaI fragment containing nt
6897 to 7365v
from pYFM5.2(del)-
SphI (containing the SPYF sequence
from nt
7444 to 8027) was ligated. This resulted in incorporation
of the SPYF
sequence from 7444 to 8027 into pYFM5.2(del)-partial
BanII.
Both this plasmid and the pYFM5.2 plasmid containing the
SPYF sequence
from nt 5459 to 6797 were digested with
NgoMIV and
XbaI and the 6701-to-7365v fragment from
pYFM5.2(del)-partial
BanII was ligated into pYFM5.2
containing the SPYF sequence from
nt 5459 to 6797, thereby
incorporating the SPYF sequences from
nt 5459 to 6701 and nt 7444 to
8027 into pYFM5.2. This ligation
resulted in the loss of the
nonsynonymous SPYF substitution at
nt 6758 from this construct. The
SPYF sequence from nt 1655 to
5108 was then introduced from pYFM5.2
harboring this SPYF sequence
via a common
NsiI/
NheI fragment (nt 1655 to 5459). The deleted
SPYF 6758 substitution was then restored by a three-piece ligation
in
which both pYFM5.2 containing the SPYF sequences from nt 1655
to 5108, 5459 to 6701, and 7444 to 8027 and the pYFM5.2 plasmid
containing the
SPYF sequence from nt 5459 to 6797 were digested
with
NgoMIV
and
AvaI. The 6701-to-6797 bp fragment from the latter
plasmid was ligated into the corresponding site in the first plasmid
to
produce pYFM5.2 containing the SPYF sequences from nt 1655
to 5108, 5459 to 6797, and 7444 to 8027. This final pYFM5.2 plasmid
lacks two
synonymous SPYF substitutions at nt 5338 and 8212 which
do not alter
the predicted amino acid sequence of the SPYF virus.
The nt 8212 substitution was omitted since it otherwise restores
an intentionally
deleted
XhoI site in pYFM5.2 which is needed
for
linearization of full-length templates (
51).
The full-length template for synthesis of RNA transcripts was assembled
by in vitro ligation of appropriate restriction enzyme
fragments as
described previously (
55). RNA transcription was
carried
out in the presence of 5'-methyl G-cap analog, SP6 RNA
polymerase (New
England Biolabs), and 50 to 100 ng of full-length
DNA template. RNA was
transfected onto Vero cell monolayers using
Lipofectamine (Gibco/BRL),
and media were harvested between 72
and 120 h postinfection in
various experiments. Virus yields were
quantitated by plaque assay on
Vero cells as described
above.
Virus growth curves.
Viruses were inoculated onto monolayers
of SW-13, BHK, or Vero cells at 37°C or onto C6/36 cells at 30°C in
triplicate wells at low multiplicities of infection (see legends to
Fig. 4 and 6), and media were harvested at 24-h intervals, followed by
replacement with fresh media. Virus yields were determined by plaque
assay on Vero cells.
 |
RESULTS |
Properties of the neuroadapted SPYF virus.
Serial passage of
YF17D virus in mouse brain is known to result in enhanced
neurovirulence for young adult mice relative to nonpassaged virus. In a
previous study, when such neuroadapted virus was tested by inoculation
of the olfactory bulb, it replicated more rapidly, generated a higher
CNS virus burden, and caused earlier death than the nonadapted virus
(55). In that study it was shown that there was genetic
heterogeneity in the E protein of the neuroadapted strain, from which
clones were derived directly from the original suckling mouse brain
virus preparation. Hence we subsequently generated plaque-purified
virus isolates from this stock and verified the neurovirulence
properties prior to molecular cloning of the full-length SPYF genome.
The original PYF virus (55) was passaged in adult SCID
mice, followed by plaque purification of the brain-associated virus,
amplification in mouse brain, and final growth in cell culture to
provide a working virus stock free of mouse brain substances. This
preparation, referred to as SPYF virus, was tested for virulence in
SCID/ICR mice using YF5.2iv virus (derived from YF17D infectious
clone), which had undergone the same plaque purification steps
except for the passages in mice, as a control. Previous studies
with YF5.2iv virus derived from this clone indicate that it has
properties which generally resemble the YF17D vaccine (17, 33,
43, 55), although there are a few sequence differences between
the two viruses (see below). Figure 1
shows the survival data for SCID/ICR mice subjected to i.p. inoculation
with the SPYF and YF5.2iv viruses. SPYF caused a fatal encephalitis
with an average incubation period of approximately 11 days (range, 8 to
21 days), whereas death associated with the YF5.2iv virus required
considerably longer (average survival time, 20 weeks; minimum survival
time, 46 days; range, 46 to 259 days [12 mice analyzed]). In some
cases, YF5.2iv-inoculated mice have survived for prolonged periods
(beyond 1 year) and no virus was recovered from the CNS at the time of death. In Fig. 1, SPYF-MN refers to the engineered cDNA clone of SPYF
which is discussed below.

View larger version (13K):
[in this window]
[in a new window]
|
FIG. 1.
Mortality data for SCID/ICR mice inoculated with
106 PFU of SPYF, YF5.2iv, or SPYF-MN viruses by the i.p.
route. Experimental procedures were carried out as described in
Materials and Methods. The mortality curves were constructed using data
from three separate experiments in which similar survival times were
recorded within groups of mice inoculated with the same viruses.
|
|
Virus distribution in tissues of SCID mice.
Experiments were
next done to determine the distribution and content of SPYF virus in
the SCID/ICR mice at the time of fatal encephalitis using plaque
titration of tissue homogenates. This method was found to be sensitive
for detection of even low levels of infectious virus (approximately 1 log PFU/g of tissue) from these animals. Results are shown in Fig.
2. High levels of SPYF virus were
measured in the brains. The average content was approximately 8.2 log
PFU/g at the time of onset of a moribund condition in such animals. A
range of peripheral tissues was also tested for virus content. Almost
all tissues tested from several individual mice contained measurable
amounts of virus; however, there was variability in the levels
detected. Moderate levels were found in lungs and adrenal glands
(approximately 4 log PFU/g). Somewhat lower levels of virus were found
in the hindlimb muscle, the kidneys, and the peritoneal membrane at the
site of virus inoculation. The lowest levels were found in the livers
and spleens (approximately 1 log PFU/g). Virus was detectable in the
blood of these mice at approximately 2 log PFU/ml. Some of the tissues
that did not yield direct plaque titers were found to contain
infectious virus by culture of the tissue extract in liquid medium on
Vero cells and plaque titration of the medium from the subculture,
indicating that they harbored virus below the limit detectable by
plaque assay.

View larger version (20K):
[in this window]
[in a new window]
|
FIG. 2.
Content of SPYF virus in tissues of SCID/ICR mice which
had been inoculated by the i.p. route as for Fig. 1. Procedures were
performed as described in Materials and Methods. Virus content is shown
as mean PFU per gram of infected tissue, plus or minus the standard
deviation, based on titrations done on three to five mice for each
group, except for lung tissue content (average of two samples). Plaque
assays were performed on Vero cells. Tissues were harvested on days 9, 10, 11, 12, and 15 after inoculation, when individual mice showed signs
of encephalitis.
|
|
Virulence properties of SPYF in normal mice.
As described in a
previous investigation (55), the parental PYF virus
exhibits high neurovirulence in normal mice by i.c. inoculation,
relative to nonneuroadapted YF5.2iv virus. To determine if SPYF
exhibited a similar increased virulence for normal mice, a graded dose
i.c. challenge was conducted in comparison to the YF5.2iv virus.
Five-week-old ICR mice (Harlan) were used in this experiment. Both
viruses caused mortality in all mice tested of this age, even at a dose
of 1.0 PFU (Fig. 3A). However, average survival times for the SPYF virus were significantly shorter than for
YF5.2iv for all doses tested (P < 0.05; two-sided
Wilcoxon test). This suggested more rapid replication of the SPYF
strain in the brains of these mice, which is consistent with the
studies of neuroadapted virus production in infected mouse brain
(55). To determine if any fatal neuroinvasiveness occured
with the SPYF virus, normal ICR mice (Taconic; same ICR background as
the SCID/ICR lineage) were tested by i.p. inoculation. In experiments
with weanling mice inoculated with the same doses of virus used for the
SCID/ICR experiments, six of eight of these mice succumbed to
peripheral inoculation with SPYF (average survival time, 9.33 days),
whereas zero of eight succumbed after inoculation with YF5.2iv
(P < 0.05) (Table 1). To
determine if the susceptibility to SPYF was age dependent, 5-week-old
mice were also tested. In this case, SPYF still caused substantial
mortality (4 of 10 mice; average survival time, 10.5 days) (Table 1).
The quantities of SPYF virus in the brains were 7.18 and 7.32 log PFU/g
(two mice in the 3-week-old group) and 6.9 and 7.32 log PFU/g (two mice in the 5-week-old group). These results were somewhat surprising because the original PYF virus preparation does not exhibit this degree
of neuroinvasiveness in adult mice (data not shown). More subtle
measures of increased virulence, such as the occurrence of subclinical
neuroinvasion with either SPYF or the YF5.2iv virus in mice which did
not succumb to infection, were not analyzed in these experiments. The
ICR mice which succumbed to infection with SPYF virus in these
experiments were also tested for viremia using a direct plaque assay as
shown in Fig. 2. No viremia was detectable in these samples, despite
the progression to lethal encephalitis in these animals.

View larger version (16K):
[in this window]
[in a new window]
|
FIG. 3.
Average survival times of ICR mice (Harlan) subjected to
graded dose i.c. inoculations. (A) SPYF compared to YF5.2iv virus. (B)
SPYF-MN compared to YF5.2iv virus. Groups of five to six mice at 5 weeks of age were used for these experiments. Average survival times in
days (means ± standard deviations) are shown. Differences between
SPYF and YF5.2iv were significant for all doses (see text). Differences
between SPYF-MN and YF5.2iv were significant for both doses (see
text).
|
|
Growth efficiency of SPYF in cell culture.
To determine if the
neurovirulence phenotypes of the SPYF and YF5.2iv viruses correlated
with any differences in replication in cell culture, the two viruses
were compared for growth efficiency in several different cell lines
(Fig. 4). In all mammalian cell lines
tested, SPYF exhibited less efficient replication, as indicated by the
rate of virus production over the first 24 to 48 h. This was most
pronounced in BHK cells (panel A), where virus yields at 24 h
differed by approximately 2 logs. Differences of 0.5 to 1.0 log were
observed in the other cell lines at 24 h (panels B, C, and D).
Peak titers of virus occurred between 48 and 72 h for both viruses
in BHK and Vero cells, reaching approximately 6 log of virus per ml. On
SW-13 and C6/36 cells, SPYF exhibited lower titers than YF5.2iv over
the interval examined. The plaque efficiency of the two viruses also
differed. SPYF formed more distinct plaques on Vero cells than YF5.2iv
did, but they were slightly smaller in size (0.9 versus 0.8 mm). In
contrast, on SW-13 cells, SPYF formed small indistinct plaques of <0.5
mm, whereas YF5.2iv formed larger distinct plaques (2 to 3 mm) (data not shown).

View larger version (25K):
[in this window]
[in a new window]
|
FIG. 4.
Growth curves of SPYF and YF5.2iv viruses in cell
culture. Experiments were conducted as described in Materials and
Methods, using multiplicities of infection of 0.03 PFU/cell. Samples
were obtained in triplicate and titrated on Vero cells, and values
indicate mean log PFU/ml ± standard deviation. (A) BHK cells. (B)
SW-13 cells. (C) Vero cells. (D) C6/36 cells.
|
|
Nucleotide sequence analysis of the SPYF virus.
In order to
define the extent of nucleotide substitutions which differentiated the
genome of the SPYF virus from nonneuroadapted YF5.2iv, the entire SPYF
genome was sequenced for duplicate reverse transcription-PCR-derived
clones from the plaque-purified virus isolate described above. A total
of 29 nucleotide substitutions were identified in the SPYF sequence
relative to that of YF5.2iv. The differences were distributed
throughout many regions of the viral genome (Fig.
5 and Table
2). One of the two clones contained a
silent substitution (an A-to-T transversion at nt 4150), but otherwise
all nucleotide and predicted amino acid substitutions were the same for
the two clones. The E protein contained the most amino acid differences
of all the proteins. These occurred at amino acid positions 52, 173, 305, 326, and 380 (numbering relative to the amino terminus of E). A
single amino acid substitution was present in the NS1 protein. The NS2A
protein contained three substitutions, the NS4A and NS4B proteins each
contained one substitution, and the NS5 protein contained two predicted
substitutions. Two substitutions were identified in the 3' untranslated
region. To gain insight into whether any of the SPYF substitutions were
likely to represent virulence determinants, the sequence of SPYF was compared with those of other YFV strains known to exhibit a high level
of virulence (Table 2). Comparison of these nucleotide and amino acid
substitutions revealed that nine of the nucleotide substitutions of
SPYF were identical to those of the Asibi, FNV, and FVV viruses,
resulting in seven amino acid identities (positions 52, 173, and 380 of
the E protein, position 173 of NS2A, position 107 of NS4A, position 232 of NS4B, and position 657 of NS5). Two other SPYF substitutions
occurred at positions where the virulent strains differ from YF5.2iv,
but these involved replacement with a different residue (position 305 of E and position 169 of NS2A). At one position (NS2A residue 17), SPYF
contained the residue found in the FNV strain. Nucleotide sequence
changes previously reported in the prM-through-NS2A region of the
original PYF viral genome (55) were also identified in the
SPYF sequence. It is important to point out that the sequence of the
YF5.2iv virus differs from the consensus sequence of YF17D (17D-204)
(50) at three nucleotide positions (nt 8212, C to T
[silent]; nt 4025, G to A [methionine to valine at NS2A residue
173]; and nt 5641, G to A [silent]) (51). Although SPYF
contains valine at NS2A residue 173, a subclone of the YF17D-204 strain
also contains this residue (50), suggesting that it is not
a critical virulence determinant.

View larger version (10K):
[in this window]
[in a new window]
|
FIG. 5.
Schematic of the YFV genome with its open reading frame,
5' and 3' untranslated regions, and positions of nucleotide and amino
acid substitutions between SPYF and YF5.2iv viruses. Amino acid
substitutions are shown above the genome. Silent nucleotide changes and
those in the 3' untranslated region are shown below the genome.
Residues or nucleotides which are common to SPYF, Asibi, FNV, and/or
FVV are marked with dark shading. Open circles and squares indicate
changes unique to SPYF. Diagonal shading indicates the position where
differences occur among YF5.2iv, SPYF, and the virulent YFV strains
(Asibi, FNV, and FVV). Horizontal shading indicates identity with FNV
(residue 17; NS2A) or with Asibi and FVV (nucleotide 1432).
|
|
Taken together, these results suggest that the identified substitutions
in SPYF most likely represent consensus sequence elements
among
virulent YF viruses and not random errors introduced by
the cloning
procedures during derivation of SPYF. However, residue
326 of the E
protein may represent a clonal substitution unique
to the plaque
isolate of SPYF derived in these experiments, since
it is not present
in the other virulent YFV strains. The glutamate
substitution is also
not found in the parental PYF preparation,
which has a lysine residue
at this position (
55). Silent nucleotide
changes between
SPYF and YF5.2iv were found at 14 positions and
were of two types. Nine
of these were unique to SPYF, and five
were common to Asibi and other
virulent strains. The two mutations
in the 3' terminus of the genome
were unique to the SPYF
virus.
Construction and properties of the SPYF-MN infectious clone.
To assess the importance of the multiple nucleotide substitutions
identified in the SPYF virus for the neurovirulence phenotype, they
were introduced into the YF5.2iv infectious clone to evaluate whether
the resulting virus would exhibit the properties of the parental SPYF
virus. All nucleotide substitutions except for two silent changes (nt
5338 and 8212) were introduced. Transfection of Vero cell monolayers
with RNA transcripts derived from the template yielded infectious virus
within approximately 5 days. The plaque size of this virus (hereafter
referred to as SPYF-MN) on SW-13 cells was small (1 mm), resembling
that of the parental SPYF virus, but was larger in size (2.5 mm) and
more distinct on Vero cells. This presumably reflected the clonal
nature of the virus derived from the neuroadapted PYF strain, which
does exhibit some heterogeneity in plaque size. Further
characterization of the SPYF-MN virus included growth curve studies in
BHK and SW-13 cells in comparison to the YF5.2iv and SPYF viruses (Fig. 6). These experiments revealed that
SPYF-MN was impaired in replication efficiency in both cell lines
relative to YF5.2iv, particularly in BHK cells. However, it replicated
more efficiently than the parental SPYF virus, with levels of virus
production intermediate between SPYF and YF5.2iv.

View larger version (14K):
[in this window]
[in a new window]
|
FIG. 6.
Growth curve analysis of SPYF, SPYF-MN and YF5.2iv
viruses in BHK and SW-13 cells. Experimental procedures were as for
Fig. 4, except that the multiplicity of infection in this experiment
was 0.003 PFU per cell. (A) BHK cells. (B) SW-13 cells.
|
|
Virulence properties of the SPYF-MN virus.
To determine if the
virulence properties of the engineered SPYF-MN virus resembled those of
its parental SPYF virus, SCID/ICR mice were tested for their
susceptibility using the experimental design shown in Fig. 1. The
average time to fatal encephalitis caused by the SPYF-MN virus in
SCID/ICR mice was 20 days (range, 11 to 35 days). This was similar to
the average survival time of 11 days for the SPYF parent, but the
difference was significant (Fig. 1) (P < 0.05;
Wilcoxon test). However, the difference in average survival time
between SPYF-MN and the YF5.2iv virus (20 weeks) was highly significant
(P < 0.01). Thus, the SPYF-MN virus was not exactly
identical to the parental SPYF virus in its virulence properties for
SCID/ICR mice but could be classified as highly virulent relative to
the YF5.2iv virus. To determine if the neuroinvasiveness of SPYF-MN
was restricted to SCID/ICR mice, normal ICR mice (Taconic) at 3 weeks
of age received the same i.p. dose as was used in the SCID/ICR
experiments. In this case, SPYF-MN did not exhibit any apparent
neuroinvasiveness, with all mice appearing healthy during the
observation period (Table 1). This was in contrast to the results with
the SPYF virus, which as stated earlier was neuroinvasive in both 3- and 5-week-old mice, with mortalities of 75 and 40% in these
respective groups.
To further compare the virulence properties of the SPYF-MN virus
with its SPYF parent, tissue titration studies were performed
on the
SCID/ICR mice which had succumbed to infection in order
to determine
the distribution and extent of virus burden at the
time of fatal
encephalitis (Fig.
7). The virus content
in tissues
of these mice was distributed similarly to that in mice
infected
with SPYF (Fig.
2), but in some cases the magnitude differed.
Titers of brain-associated virus were essentially the same as
those
observed with SPYF (8.2 log PFU/g). Virus was isolated in
similar
amounts from adrenal glands (approximately 4.0 log PFU/g).
Most other
tissues contained quantities of titratable virus similar
to those seen
with the SPYF virus, except lower levels were found
in the lungs, and
the viremia was between 0.5 and 1.0 log PFU/ml
lower than with the SPYF
virus. Taken together, these results
suggest that some or all of the
genetic determinants introduced
into the SPYF-MN virus govern
replication efficiency in the peripheral
tissues of SCID mice, in
conjunction with their effects on inducing
fatal encephalitis in this
host.

View larger version (18K):
[in this window]
[in a new window]
|
FIG. 7.
Content of SPYF-MN virus in tissues recovered from
SCID/ICR mice after i.p. inoculation as in Fig. 1. Experimental
procedures were as described for Fig. 2. Values (mean log PFU/g ± standard deviation) were determined from between four and seven mice in
these experiments. Tissues were harvested on days 15 (two mice), 17, 20, 23, 24, and 33, when individual mice showed signs of
encephalitis.
|
|
To further investigate the relationship between replication of YFV in
peripheral tissues and the occurrence of encephalitis,
experiments were
done to see if the YF5.2iv virus generated a
virus burden in SCID mouse
tissues similar to those seen with
the SPYF and SPYF-MN viruses. Three
SCID/ICR mice infected with
YF5.2iv were sacrificed at the same time
that mice inoculated
with SPYF-MN were succumbing to encephalitis
(between 2 and 3
weeks postinfection), and virus contents were
determined in the
tissue homogenates as for Fig.
2 and
7. The
peripheral tissues
and brains of these mice were devoid of any
detectable virus based
on plaque assay, except for a single sample of
peritoneal membrane
from one mouse which yielded 2 log PFU/g. Thus, a
lower virus
burden is present in mice infected with the YF5.2iv
virus at the
time that mice infected with SPYF-MN have accumulated
their peak
virus burdens, despite similar doses of the two viruses
being
administered. This suggests that YF5.2iv is either less
infectious
or replicates less efficiently in mouse tissues than SPYF
and
SPYF-MN.
Because of the large difference in survival time between SCID/ICR mice
infected with YF5.2iv virus by the i.p. route and those
infected with
the SPYF and SPYF-MN viruses, experiments were done
to determine if the
incubation time for fatal encephalitis after
i.c. inoculation differed
among the three viruses. Although this
seemed an unlikely possibility,
it was not known how the absence
of an immune system in SCID mice would
influence the behavior
of virus after entry into the CNS. For these
experiments, dose
ranging was done at low doses (0.5 to 100 PFU per
mouse), which
was predicted to mimic the amount of virus entering the
brain
during neuroinvasion following peripheral infection (based on
the
viremia data shown in Fig.
2 and
7). As shown in Table
3,
100% mortality was observed with as
little as 5 PFU of SPYF virus,
but this dose was sublethal for both
SPYF-MN and YF5.2iv. Differences
between the average survival times for
SPYF and either SPYF-MN
or YF5.2iv at this dose were significant
(
P = 0.025), but the
difference between SPYF-MN and
YF5.2iv was not. A dose of 100
PFU caused 100% mortality with both the
SPYF-MN and YF5.2iv viruses;
however, the difference between the
average survival times at
this dose was significant (11 versus 23 days;
range, 10 to 12
days versus 10 to 56 days, respectively). Although the
average
survival time appeared longer for mice receiving 100 PFU of
YF5.2iv
virus than for those receiving 5 PFU, it is important to note
that only three of five mice died in the latter group. All mice
inoculated with 0.5 PFU of virus survived, except for one recipient
of
SPYF-MN which died 11 days postinoculation. The brain content
of virus
at the time of onset of the moribund condition was determined
for
mice receiving the SPYF-MN and YF5.2iv viruses. Values of
7.64 and
8.14 log PFU/g were obtained for SPYF-MN (two mice tested).
Values of
7.19, 7.43, and 7.27 log PFU/g were obtained for YF5.2iv
(three mice
tested).
The neurovirulence of the SPYF-MN and YF5.2iv viruses was also compared
in normal ICR mice (Harlan) (Fig.
3B). At two doses,
10 and 100 PFU
delivered by i.c. inoculation, mortality was 100%
for both viruses.
Average (± standard deviation) survival times
were 9.14 ± 1.0 and 8.0 ± 0.8 days for these doses of SPYF-MN
versus
10.16 ± 0.75 and 9.66 ± 0.5 days for YF5.2iv, respectively,
and were significantly different between the two viruses in both
cases
(
P < 0.05). Taken together, the data from these
various
experiments indicate that SPYF is the most virulent of these
viruses
and that SPYF-MN is more virulent than YF5.2iv for SCID and
normal
ICR mice, based on mortality rates and average survival times.
The failure of the YF5.2iv virus to cause rapidly fatal infection
in
SCID mice did not result from an inability to replicate in
the CNS of
these mice, since lethal virus burdens could be generated
in some cases
if a sufficient quantity of virus was introduced
(between 5 and 100 PFU). The average incubation times for fatal
encephalitis with the
three viruses after i.c. inoculation in
SCID mice ranged from 9 to 23 days and differences were statististically
significant among the
groups. It is also notable that the neuroadapted
viruses were more
virulent for ICR mice (Harlan) than for SCID/ICR
mice of the same age,
both in terms of dose required for 100%
mortality and average survival
time (compare Fig.
3 and Table
3). This could reflect differences
in susceptibility to YFV among
outbred mice of different lineages,
as observed previously (
4),
or some differential effect
associated with the SCID mutation
itself on viral
pathogenesis.
 |
DISCUSSION |
YF17D, similar to other flaviviruses, exhibits a high level of
neurovirulence when introduced into the CNS of mice but usually does
not cause fatal encephalitis following infection of immunocompetent adult mice by a peripheral route of inoculation. It has been observed that the incubation time for the encephalitis can be measurably shortened by serial passage of the virus in mouse brain, and this process is associated with selection for viruses with enhanced replication efficiency in neural tissue (37, 56, 59).
Direct comparison of the replication efficiencies and virulence
properties in mouse brain of genetically defined strains of
neuroadapted and nonneuroadapted flaviviruses is therefore an approach
to defining the virus-specific factors which govern this process and is
a first step towards understanding the mechanisms involved in the pathogenesis of encephalitis in this model.
The E protein is a major virulence factor for flaviviruses, with
numerous studies demonstrating that determinants within this protein
affect virulence in the mouse model (reviewed in reference 36; see also references 10, 32, 45, 46, 52,
and 54). It is becoming evident, however, that other
molecular determinants involved in the functions of either
nonstructural proteins or the 5' and 3' untranslated regions also
influence the virulence phenotypes of flaviviruses (7, 14, 31,
38, 43, 47). To gain insight into this process, we
determined the genomic sequence of a neurovirulent plaque isolate
selected from the mouse-neuroadapted PYF strain. This study differs
from various other investigations using engineered virus mutants
because the substitutions we identified are directly related to the
process of neuroadaptation and their presence in other highly virulent
strains such as Asibi and FVV suggests a strong association with the
virulence phenotype. The multiple sequence differences detected in the
SPYF virus compared to nonneuroadapted virus were unlikely to represent
deleterious mutations accumulated during plaque purification or
molecular cloning, since virus engineered to contain the substitutions
displayed cell culture properties that were generally similar to the
original SPYF virus. In studies of virulence, this SPYF-MN molecular
clone was also similar to the SPYF parent based on neuroinvasiveness and neurovirulence for SCID/ICR mice. In normal ICR mice, however, SPYF-MN differed from SPYF in being nonneuroinvasive but had
neurovirulence properties which were of a higher grade than the YF5.2iv
virus (based on average survival times; Fig. 3B). Thus, the SCID mouse was a more sensitive model than normal mice to discriminate the genetic
basis for virulence determinants of YFV. This failure to reconstruct a
full virulence phenotype using cDNA-derived virus clones has been
observed with other neurotropic flaviviruses (9). In
the present case, this may result from clonal differences in neurovirulence determinants among viruses in the heterogeneous SPYF
pool. Alternatively, mutations introduced by SP6 transcription during
synthesis of infectious RNA transcripts could confer properties on the
virus which reduce the effects of neurovirulence determinants. However,
the results do indicate that one or more of the nucleotide sequence
differences identified between the YF5.2iv and SPYF-MN viruses largely
governs the virulence of SPYF for SCID/ICR mice. Since some of the
substitutions observed in SPYF were common to the Asibi, FVV, and FNV
viruses, it is not likely that they are sequence artifacts unrelated to
the neurovirulence phenotype.
With respect to the E protein, it is believed that molecular
determinants distributed throughout domains I, II, and III, as well as
the stem-anchor region, are critical for the structural changes in this
protein which are required for virus entry (1, 2, 21, 57).
Mutations at numerous positions are in turn capable of modulating the
virulence properties conferred by this protein (49). This
has generally been the case for encephalitic flaviviruses which have
been characterized in mice (36). Consistent with this
hypothesis, predicted amino acid substitutions were found in domains I,
II, and III in the E protein of the SPYF virus. Mutation at residue 52 has been associated with neurovirulence differences and alterations of
virus-cell interactions for Japanese encephalitis (JE) virus
(20). Position 173 has been identified as a site which
defines a YFV wild-type epitope and is associated with altered
neurovirulence of YF17D virus (52). Positions 326 and 380 lie within the putative receptor binding domain at two distinct regions
which have been proposed as critical for the function of this portion
of the E protein (6). A YF17D substrain-specific epitope
is known to involve the adjacent residue 325, whose substitution is
associated with alteration in mouse neurovirulence (54). Residue 380 is included within the RGD motif of mosquito-borne flaviviruses, in which mutations have been shown to affect the efficiency of virus spread in cell culture and neuroinvasion in mice
(29, 60). Collectively, these observations suggest that the substitutions in the SPYF E protein are likely to functionally alter its properties during pathogenesis of encephalitis in the mouse
model. However, unlike cases where as few as two residues govern the
neurovirulence of a flavivirus (23), the presence of five
substitutions in the E protein of SPYF suggests that neurovirulence may
depend on multiple genetic determinants, as has been shown in studies
of the JE virus E protein (4). Fine mapping of these candidate virulence determinants within the SPYF E protein using the
SCID/ICR mouse model will allow identification of the critical residues
and may give insight into potential mechanisms underlying the
neuroinvasive and neurovirulence properties of this virus. Since the
effects of substitutions in the nonstructural region on neurovirulence
have not been determined, it is premature to conclude that the E
protein is the only protein responsible for the enhanced neurovirulence
of SPYF. Studies on the attenuation of the Asibi strain of YFV suggest
a selection for mutations in the E protein as well as nonstructural
proteins, even after limited passages in cell substrates (14,
18). In particular, substitutions in NS1, NS2A, NS4B, and NS5
have been noted. It is conceivable that such substitutions enhance
neurovirulence by increasing the efficiency of RNA synthesis, leading
to higher virus burdens and induction of apoptotic cell death
(13). In addition, comparison of the sequences of SPYF-MN,
Asibi, FVV, and FNV viruses reveals that some silent nucleotide
substitutions are common to these viruses. This could reflect selection
for RNA structures which impart higher replication efficiency or confer
host range effects which are important during pathogenesis. Although
this is not a well-explored area, it is increasingly being realized
that effects of mutations on RNA structures are likely to influence
flavivirus replication (48).
The pattern of disease occurring in the SCID mouse subjected to
infection with neuroadapted virus is characterized by a high virus
burden in the CNS, together with lower quantities of virus in
extraneural tissues and a relatively low-level viremia. This level of
viremia is typical of that generated by attenuated virus strains in
other rodent models of flavivirus neuropathogenesis (40, 44,
58). The presence and magnitude of viremia has generally been
regarded as an important factor for neuroinvasion (19,
41), but the consequences of a given level may depend to some
extent on the host immune response to circulating virus or the
associated virus burden in the peripheral tissues of infected animals.
The low viremia observed in this SCID/ICR model may result in part from
YFV being inherently less efficient than other encephalitic flaviviruses for replication in mice because of its evolution and
adaptation towards lymphoid tissue of primates (42). In addition, clearance by nonspecific immune defenses such as macrophages and/or natural killer cells may be a mechanism which reduces
circulating virus to relatively low levels in this model (39,
62). The higher virus burden in SCID/ICR mice inoculated with
SPYF-MN than those inoculated with YF5.2iv at 2 to 3 weeks
postinfection suggests that genetic determinants within SPYF-MN
promote more efficient replication in peripheral tissues in this host.
YF17D vaccine strains have been observed to be less infectious for mice
than virulent strains, in an age-dependent fashion (15).
The failure of YF5.2iv to generate much virus burden in SCID/ICR mice
may therefore reflect a low efficiency of infection even at the doses used in our experiments. Alternatively, resistance of SPYF to clearance
by the innate immune response has not been eliminated as an explanation
for the observed differences in virus burden. For instance, evidence
exists from studies of other flavivirus infections in SCID mice that
alpha and beta interferons play important roles in host defense against
this family of viruses (24, 27), but there is little
information available on virus-host interactions at this level
(12).
The difference between SPYF and SPYF-MN with respect to mortality of
normal ICR mice inoculated by the peripheral route is also notable.
This difference could be based on a highly neuroinvasive quasispecies
within the SPYF population which is not represented by SPYF-MN.
Alternatively, if a certain threshold of viremia is required for
neuroinvasion, SPYF may be more efficient in achieving this prior to
induction of sufficient neutralizing antibody activity and/or cytotoxic
T lymphocytes which then act to eliminate cirtculating virus. In
contrast to what was observed in SCID/ICR mice, the absence of
detectable viremia in ICR mice at the time of fatal encephalitis is
consistent with the clearance of circulating virus by such mechanisms
(41).
The average incubation time to onset of fatal encephalitis after i.c.
inoculation of SCID/ICR mice with YF5.2iv virus was somewhat longer
than for the SPYF and SPYF-MN viruses (Table 3); however, the time
interval between peripheral inoculation and death was considerably
longer (Fig. 1). A difference was also observed in the amount of virus
required to cause lethal encephalitis after i.c. inoculation of these
mice with the three viruses, with SPYF-MN and YF5.2iv being sublethal
at doses at or below 5 PFU (Table 3). These results suggest that the
time required for neuroinvasion is the principle variable which
accounts for the prolonged delay before onset of encephalitis with
YF5.2iv virus. However, entry of only small amounts of YF5.2iv virus
(<5 PFU) may not always be sufficient to generate a lethal infection
in the CNS. Hence, differences in neuroinvasiveness and neurovirulence
may both be involved in the virulence properties of SPYF compared to
YF5.2iv in SCID/ICR mice. The long incubation time of the
nonneuroadapted virus presumably reflects a requirement for
accumulation of a virus burden in peripheral tissues. In this regard,
neuroadaptation of YF17D virus may reflect a generalized adaptation to
mouse tissue which is the basis for the more efficient replication of
SPYF than of YF5.2iv virus in all extraneural tissues examined. It is
possible that nonspecific immune defenses may be more efficient in
clearing virus from peripheral tissues than from the CNS, which could
also contribute to the long interval needed for accumulation of YF5.2iv
virus prior to neuroinvasion. Clearly, the level of virus burden
appears to be related to the occurrence of neuroinvasion. It is not
known whether neuroinvasion results from a critical level of
circulating virus or requires participation of inflammatory responses
from nonspecific host defenses such as activated macrophages and
natural killer cells, as suggested by other models (30). In any case, due to the multiple number of nucleotide substitutions between the SPYF-MN and YF5.2iv viruses, further studies with engineered mutants are needed to establish whether the determinants which enhance growth of virus in the periphery and those which promote
neuroinvasion also govern replication efficiency in the CNS. It will
also be of interest to establish whether there is a redundancy in the
effects of multiple independent mutations on the virulence phenotype or
whether certain residues have dominant effects. The mechanism of
enhanced neurovirulence of neuroadapted YFV has been proposed to
involve the generation of a high virus burden in the CNS resulting from
an enhanced replication efficiency and leading to death of target cells
(55). Other mechanisms could also contribute to neuronal
death, including deleterious effects of the virus-specific inflammatory
response. In the SCID model this is certainly not the case, although a
detailed analysis of the CNS inflammatory response is needed to
determine the role of nonspecific host immune responses, which have
been implicated in the pathogenesis of Murray Valley encephalitis virus
(3).
Finally, it remains undetermined whether any mutations occur in the
YF5.2iv virus during the long incubation period preceeding the onset of
encephalitis which occurs in some mice infected with this
nonneuroadapted virus. If so, this might reflect emergence of viruses
with an increase in neurovirulence. Evolution of virulent viruses
during persistent infection of SCID mice with Sindbis virus has been
described as a virus-specific mechanism of pathogenesis (26). This question is under investigation for YFV using
brain-associated virus recovered from mice which have succumbed to
infection with YF5.2iv virus after prolonged time intervals.
 |
ACKNOWLEDGMENTS |
This work was supported by grants from the NIH (AI-37646) and the
Edward Mallinckrodt, Jr., Foundation.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Molecular Microbiology and Immunology, St. Louis University Health
Sciences Center, 1402 S. Grand Ave., St. Louis, MO 63104. Phone: (314) 577-8447. Fax: (314) 773-3403. E-mail: chambetj{at}slu.edu.
 |
REFERENCES |
| 1.
|
Allison, S. L.,
J. Schalich,
K. Stiasny,
C. W. Mandl,
C. Kunz, and F. X. Heinz.
1995.
Oligomeric rearrangement of tick-borne encephalitis virus envelope proteins induced by an acidic pH.
J. Virol.
69:695-700[Abstract].
|
| 2.
|
Allison, S. L.,
K. Stiasny,
K. Stadler,
C. W. Mandl, and F. X. Heinz.
1999.
Mapping of functional elements in the stem-anchor region of tick-borne encephalitis virus envelope protein E.
J. Virol.
73:5605-5612[Abstract/Free Full Text].
|
| 3.
|
Andrews, D. M.,
V. B. Matthews,
L. M. Sammels,
A. C. Carrello, and P. C. McMinn.
1999.
The severity of Murray Valley encephalitis in mice is linked to neutrophil infiltration and inducible nitric oxide synthase activity in the central nervous system.
J. Virol.
73:8781-8790[Abstract/Free Full Text].
|
| 4.
|
Arroyo, J.,
F. Guirakhoo,
S. Fenner,
Z.-X. Zhang,
T. P. Monath, and T. J. Chambers.
2001.
Molecular basis for attenuation of neurovirulence of a yellow fever virus/Japanese encephalitis virus chimera vaccine (ChimeriVax-JE).
J. Virol.
75:934-942[Abstract/Free Full Text].
|
| 5.
|
Barrett, A. D. T., and E. A. Gould.
1986.
Comparison of neurovirulence of different strains of yellow fever virus in mice.
J. Gen. Virol.
67:631-637[Abstract/Free Full Text].
|
| 6.
|
Bhardwaj, S.,
M. Holbrook,
R. E. Shope,
A. D. T. Barrett, and S. J. Watowich.
2001.
Biophysical characterization and vector-specific antagonist activity of domain III of the tick-borne flavivirus envelope protein.
J. Virol.
75:4002-4007[Abstract/Free Full Text].
|
| 7.
|
Bray, M.,
R. Men,
I. Tokimatsu, and C.-J. Lai.
1998.
Genetic determinants responsible for acquisition of dengue type 2 virus mouse neurovirulence.
J. Virol.
72:1647-1651[Abstract/Free Full Text].
|
| 8.
|
Butrapet, S.,
C. Y.-H. Huang,
D. J. Pierro,
N. Bhamarapravati,
D. J. Gubler, and R. M. Kinney.
2000.
Attenuation markers of a candidate dengue type 2 vaccine virus, strain 16681 (PDK-53), are defined by mutations in the 5' noncoding region and nonstructural proteins 1 and 3.
J. Virol.
74:3011-3019[Abstract/Free Full Text].
|
| 9.
|
Campbell, M. S., and A. G. Pletnev.
2000.
Infectious clones of Langat tick-borne flavivirus that differ from their parent in peripheral neurovirulence.
Virology
269:225-237[CrossRef][Medline].
|
| 10.
|
Chambers, T. J.,
A. Nestorowicz,
P. W. Mason, and C. M. Rice.
1999.
Yellow fever/Japanese encephalitis chimeric viruses: construction and biological properties.
J. Virol.
73:3095-3101[Abstract/Free Full Text].
|
| 11.
|
Despres, P.,
M.-P. Frenkiel,
P.-E. Ceccaldi,
C. Duarte dos Santos, and V. Deubel.
1998.
Apoptosis in the mouse central nervous system in response to infection with mouse-neurovirulent dengue viruses.
J. Virol.
72:823-829[Abstract/Free Full Text].
|
| 12.
|
Diamond, M. S.,
T. G. Roberts,
D. Edgil,
B. Lu,
J. Ernst, and E. Harris.
2000.
Modulation of dengue virus infection in human cells by alpha, beta, and gamma interferons.
J. Virol.
74:4957-4966[Abstract/Free Full Text].
|
| 13.
|
Duarte dos Santos, C. N.,
M.-P. Frenkiel,
M.-P. Courageot,
C. F. S. Rocha,
M.-C. Vazeille-Falcoz,
M. W. Wien,
F. A. Rey,
V. Deubel, and P. Despres.
2000.
Determinants in the envelope E protein and viral RNA helicase NS3 that influence the induction of apoptosis in response to infection with dengue type 1 virus.
Virology
274:292-308[CrossRef][Medline].
|
| 14.
|
Dunster, L. M.,
H. Wang,
K. D. Ryman,
B. R. Miller,
S. J. Watowich,
P. D. Minor, and A. D. T. Barrett.
1999.
Molecular and biological changes associated with HeLa cell attenuation of wild-type yellow fever virus.
Virology
261:309-318[CrossRef][Medline].
|
| 15.
|
Fitzgeorge, R., and C. J. Bradish.
1980.
The in vivo differentiation of strains of yellow fever virus in mice.
J. Gen. Virol.
46:1-13[Abstract/Free Full Text].
|
| 16.
|
Freestone, D. S.
1994.
Yellow fever vaccine, p. 741-779.
In
S. A. Plotkin, and E. M. Mortimer (ed.), Vaccines, 2nd ed. W. B. Saunders, Philadelphia, Pa.
|
| 17.
|
Guirakhoo, F.,
Z.-X. Zhang,
T. J. Chambers,
S. Delagrave,
J. Arroyo,
A. D. T. Barrett, and T. P. Monath.
1999.
Immunogenicity, genetic stability, and protective efficacy of a recombinant, chimeric yellow fever-Japanese encephalitis virus (ChimeriVax-JE) as a live, attenuated vaccine candidate against Japanese encephalitis.
Virology
257:363-372[CrossRef][Medline].
|
| 18.
|
Hahn, C. S.,
J. M. Dalrymple,
J. H. Strauss, and C. M. Rice.
1987.
Comparison of the virulent Asibi strain of yellow fever virus with the 17D vaccine strain derived from it.
Proc. Natl. Acad. Sci. USA
84:2019-2023[Abstract/Free Full Text].
|
| 19.
|
Halevy, M.,
Y. Akov,
D. Ben-Nathan,
D. Kobiler,
B. Lachmi, and S. Lustig.
1994.
Loss of active neuroinvasiveness in attenuated strains of West Nile virus: pathogenicity in immunocompetent and SCID mice.
Arch. Virol.
137:355-370[CrossRef][Medline].
|
| 20.
|
Hasegawa, H.,
M. Yoshida,
T. Shiosaka,
S. Fujita, and Y. Kobayashi.
1992.
Mutations in the envelope protein of Japanese encephalitis virus affect entry into cultured cells and virulence in mice.
Virology
191:158-165[CrossRef][Medline].
|
| 21.
|
Heinz, F. X.,
K. Stiasny,
G. Puschner-Auer,
H. Holtzmann,
S. L. Allison,
C. W. Mandl, and C. Kunz.
1994.
Structural changes and functional control of the tick-borne encephalitis virus glycoprotein E by the heterodimeric association with protein prM.
Virology
198:109-117[CrossRef][Medline].
|
| 22.
|
Jennings, A. D.,
J. E. Whitby,
P. D. Minor, and A. D. T. Barrett.
1993.
Comparison of the nucleotide and deduced amino acid sequences of the envelope protein genes of the wild-type French viscerotropic strain of yellow fever virus and the live vaccine strain, French neurotropic vaccine, derived from it.
Virology
192:692-695[CrossRef][Medline].
|
| 23.
|
Jennings, A. D.,
C. A. Gibson,
B. R. Miller,
J. H. Mathews,
C. J. Mitchell,
J. T. Roehrig,
D. J. Wood,
F. Taffs,
B. K. Sil,
S. N. Whitby,
J. E. Whitby,
T. P. Monath,
P. D. Minor,
P. G. Sanders, and A. D. T. Barrett.
1994.
Analysis of a yellow fever virus isolated from a fatal case of vaccine-associated human encephalitis.
J. Infect. Dis.
169:512-518[Medline].
|
| 24.
|
Johnson, A. J., and J. T. Roehrig.
1999.
New mouse model for dengue virus vaccine testing.
J. Virol.
73:783-786[Abstract/Free Full Text].
|
| 25.
|
Kawano, H.,
V. Rostapshov,
L. Rosen, and C.-J. Lai.
1993.
Genetic determinants of dengue type 4 virus neurovirulence for mice.
J. Virol.
67:6567-6575[Abstract/Free Full Text].
|
| 26.
|
Levine, B., and D. E. Griffin.
1993.
Molecular analysis of neurovirulent strains of Sindbis virus that evolve during persistent infection of scid mice.
J. Virol.
67:6872-6875[Abstract/Free Full Text].
|
| 27.
|
Leyssen, P.,
A. Van Lommel,
C. Drosten,
H. Schmitz,
E. De Clercq, and J. Neyts.
2001.
A novel model for the study of the therapy of flavivirus infections using the Modoc virus.
Virology
279:27-37[CrossRef][Medline].
|
| 28.
|
Liprandi, F.
1981.
Isolation of plaque variants differing in virulence from the 17D strain of yellow fever virus.
J. Gen. Virol.
56:363-370[Abstract/Free Full Text].
|
| 29.
|
Lobigs, M.,
R. Usha,
A. Nestorowicz,
I. D. Marshall,
R. C. Weir, and L. Dalgarno.
1990.
Host cell selection of Murray Valley encephalitis virus variants altered at an RGD sequence in the envelope protein and in mouse virulence.
Virology
176:587-595[CrossRef][Medline].
|
| 30.
|
Lustig, S.,
H. D. Danenberg,
Y. Kafri,
D. Kobiler, and D. Ben-Nathan.
1992.
Viral neuroinvasion and encephalitis induced by lipopolysaccharide and its mediators.
J. Exp. Med.
176:707-712[Abstract/Free Full Text].
|
| 31.
|
Mandl, C. W.,
H. Holzmann,
T. Meixner,
S. Rauscher,
P. F. Stadler,
S. L. Allison, and F. X. Heinz.
1998.
Spontaneous and engineered deletions in the 3' noncoding region of tick-borne encephalitis virus: construction of highly attenuated mutants of a flavivirus.
J. Virol.
72:2132-2140[Abstract/Free Full Text].
|
| 32.
|
Mandl, C. W.,
S. L. Allison,
H. Holzmann,
T. Meixner, and F. X. Heinz.
2000.
Attenuation of tick-borne encephalitis virus by structure-based site-specific mutagenesis of a putative flavivirus receptor binding site.
J. Virol.
74:9601-9609[Abstract/Free Full Text].
|
| 33.
|
Marchevsky, R. S.,
J. Mariano,
V. S. Ferreira,
E. Almeida,
M. J. Cerqueira,
R. Carvalho,
J. W. Pissurno,
A. P. A. Travassos Da Rosa,
M. C. Simoes,
C. N. D. Santos,
I. I. Ferreira,
I. R. Muylaert,
G. F. Mann,
C. M. Rice, and R. Galler.
1995.
Phenotypic analysis of yellow fever virus derived from cDNA.
Am. J. Trop. Med. Hyg.
52:75-80.
|
| 34.
|
McMinn, P. C.,
E. Lee,
S. Hartley,
J. T. Roehrig,
L. Dalgarno, and R. C. Weir.
1995.
Murray Valley encephalitis virus envelope protein antigenic variants with altered hemagglutination properties and reduced neuroinvasiveness in mice.
Virology
211:10-20[CrossRef][Medline].
|
| 35.
|
McMinn, P. C.,
R. C. Weir, and L. Dalgarno.
1996.
A mouse-attenuated envelope protein variant of Murray Valley encephalitis virus with altered fusion activity.
J. Gen. Virol.
77:2085-2088[Abstract/Free Full Text].
|
| 36.
|
McMinn, P. C.
1997.
The molecular basis of virulence of the encephalitogenic flaviviruses.
J. Gen. Virol.
78:2711-2722[Medline].
|
| 37.
|
Meers, P. D.
1959.
Adaptation of the 17D yellow fever virus to mouse brain by serial passage.
Trans. R. Soc. Trop. Med. Hyg.
53:445-457[CrossRef].
|
| 38.
|
Men, R.,
M. Bray,
D. Clark,
R. M. Chanock, and C.-J. Lai.
1996.
Dengue type 4 virus mutants containing deletions in the 3' noncoding region of the RNA genome: analysis of growth restriction in cell culture and altered viremia pattern and immunogenicity in rhesus monkeys.
J. Virol.
70:3930-3937[Abstract].
|
| 39.
|
Monath, T. P. C., and E. C. Borden.
1971.
Effects of thorotrast on humoral antibody, viral multiplication and interferon during infection with St. Louis encephalitis virus in mice.
J. Infect. Dis.
123:297-300[Medline].
|
| 40.
|
Monath, T. P.,
C. B. Cropp,
G. S. Bowen,
G. E. Kemp,
C. J. Mitchell, and J. J. Gardner.
1980.
Variation in virulence for mice and rhesus monkeys among St. Louis encephalitis virus strains of different origin.
Am. J. Trop. Med. Hyg.
29:948-962.
|
| 41.
|
Monath, T. P.
1986.
Pathobiology of the flaviviruses, p. 375-440.
In
S. Schlesinger, and M. J. Schlesinger (ed.), The togaviridae and the flaviviridae. Plenum Press, New York, N.Y.
|
| 42.
|
Monath, T. P.
1994.
Yellow fever and dengue: the interactions of virus, vector and host in the re-emergence of epidemic disease.
Semin. Virol.
5:133-143.
|
| 43.
|
Muylaert, I. R.,
T. J. Chambers,
R. Galler, and C. M. Rice.
1996.
Mutagenesis of the N-linked glycosylation sites of the yellow fever virus NS1 protein: effects on virus replication and mouse neurovirulence.
Virology
222:159-168[CrossRef][Medline].
|
| 44.
|
Ni, H., and A. D. T. Barrett.
1996.
Molecular differences between wild-type Japanese encephalitis virus strains of high and low mouse neuroinvasiveness.
J. Gen. Virol.
77:1449-1455[Abstract/Free Full Text].
|
| 45.
|
Ni, H., and A. D. T. Barrett.
1998.
Attenuation of Japanese encephalitis virus by selection of its mouse brain membrane receptor preparation escape variants.
Virology
241:30-36[CrossRef][Medline].
|
| 46.
|
Ni, H.,
K. D. Ryman,
H. Wang,
M. F. Saeed,
R. Hull,
D. Wood,
P. D. Minor,
S. J. Watowich, and A. D. T. Barrett.
2000.
Interaction of yellow fever virus French neurotropic vaccine strain with monkey brain: characterization of monkey brain membrane receptor escape variants.
J. Virol.
74:2903-2906[Abstract/Free Full Text].
|
| 47.
|
Pletnev, A. G.,
M. Bray, and C.-J. Lai.
1993.
Chimeric tick-borne encephalitis and dengue type 4 viruses: effects of mutations on neurovirulence in mice.
J. Virol.
67:4956-4963[Abstract/Free Full Text].
|
| 48.
|
Proutski, V.,
M. W. Gaunt,
E. A. Gould, and E. C. Holmes.
1997.
Secondary structure of the 3'-untranslated region of yellow fever virus: implications for virulence, attenuation and vaccine development.
J. Gen. Virol.
78:1543-1549[Abstract].
|
| 49.
|
Rey, F. A.,
F. X. Heinz,
C. Mandl,
C. Kunz, and S. C. Harrison.
1995.
The envelope glycoprotein from tick-borne encephalitis virus at 2 angstrom resolution.
Nature
375:291-298[CrossRef][Medline].
|
| 50.
|
Rice, C. M.,
E. M. Lenches,
S. R. Eddy,
S. J. Shin,
R. I. Sheets, and J. H. Strauss.
1985.
Nucleotide sequence of yellow fever virus: implications for flavivirus gene expression and evolution.
Science
229:726-733[Abstract/Free Full Text].
|
| 51.
|
Rice, C. M.,
A. Grakoui,
R. Galler, and T. J. Chambers.
1989.
Transcription of infectious yellow fever virus RNA from full-length cDNA templates produced by in vitro ligation.
New Biol.
1:285-296[Medline].
|
| 52.
|
Ryman, K. D.,
H. Xie,
T. N. Ledger,
G. A. Campbell, and A. D. T. Barrett.
1997.
Antigenic variants of yellow fever virus with an altered neurovirulence phenotype in mice.
Virology
230:376-380[CrossRef][Medline].
|
| 53.
|
Ryman, K. D.,
T. N. Ledger,
R. C. Weir,
J. J. Schlesinger, and A. D. T. Barrett.
1997.
Yellow fever virus envelope protein has two discrete type-specific neutralizing epitopes.
J. Gen. Virol.
78:1353-1356[Abstract].
|
| 54.
|
Ryman, K. D.,
T. N. Ledger,
G. A. Campbell,
S. J. Watowich, and A. D. T. Barrett.
1998.
Mutation in a 17D-204 vaccine substrain-specific envelope protein epitope alters the pathogenesis of yellow fever virus in mice.
Virology
244:59-65[CrossRef][Medline].
|
| 55.
|
Schlesinger, J. J.,
S. Chapman,
A. Nestorowicz,
C. M. Rice,
T. E. Ginocchio, and T. J. Chambers.
1996.
Replication of yellow fever virus in the mouse central nervous system: Comparison of neuroadapted and non-neuroadapted virus and partial sequence analysis of the neuroadapted strain.
J. Gen. Virol.
77:1277-1285[Abstract/Free Full Text].
|
| 56.
|
Schlesinger, R. W.
1980.
Virus-host interactions in natural and experimental infections with alphaviruses and flaviviruses, p. 83-104.
In
R. W. Schlesinger (ed.), The togaviruses. Academic Press, New York, N.Y.
|
| 57.
|
Stiasny, K.,
S. L. Allison,
A. Marchler-Bauer,
C. Kunz, and F. X. Heinz.
1996.
Structural requirements for low-pH-induced rearrangements in the envelope glycoprotein of tick-borne encephalitis virus.
J. Virol.
70:8142-8147[Abstract].
|
| 58.
|
Sumiyoshi, H.,
G. H. Tignor, and R. E. Shope.
1995.
Characterization of a highly attenuated Japanese encephalitis virus generated from molecularly cloned cDNA.
J. Infect. Dis.
171:1144-1151[Medline].
|
| 59.
|
Theiler, M.
1951.
The virus, p. 46-136.
In
G. K. Strode (ed.), Yellow fever. McGraw-Hill, New York, N.Y.
|
| 60.
|
Van der Most, R. G.,
J. Corver, and J. H. Strauss.
1999.
Mutagenesis of the RGD motif in the yellow fever virus 17D envelope protein.
Virology
265:83-95[CrossRef][Medline].
|
| 61.
|
Wang, E.,
K. D. Ryman,
A. D. Jennings,
D. J. Wood,
F. Taffs,
P. D. Minor,
P. G. Sanders, and A. D. T. Barrett.
1995.
Comparison of the genomes of the wild-type French viscerotropic strain of yellow fever virus with its vaccine derivative French neurotropic vaccine.
J. Gen. Virol.
76:2749-2755[Abstract/Free Full Text].
|
| 62.
|
Zisman, B.,
E. F. Wheelock, and A. C. Allison.
1971.
Role of macrophages and antibody in resistance of mice against yellow fever virus.
J. Immunol.
107:236-243[Abstract/Free Full Text].
|
Journal of Virology, November 2001, p. 10912-10922, Vol. 75, No. 22
0022-538X/01/$04.00+0 DOI: 10.1128/JVI.75.22.10912-10922.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Nickells, J., Cannella, M., Droll, D. A., Liang, Y., Wold, W. S. M., Chambers, T. J.
(2008). Neuroadapted Yellow Fever Virus Strain 17D: a Charged Locus in Domain III of the E Protein Governs Heparin Binding Activity and Neuroinvasiveness in the SCID Mouse Model. J. Virol.
82: 12510-12519
[Abstract]
[Full Text]
-
Lee, E., Lobigs, M.
(2008). E Protein Domain III Determinants of Yellow Fever Virus 17D Vaccine Strain Enhance Binding to Glycosaminoglycans, Impede Virus Spread, and Attenuate Virulence. J. Virol.
82: 6024-6033
[Abstract]
[Full Text]
-
Pierro, D. J., Powers, E. L., Olson, K. E.
(2008). Genetic Determinants of Sindbis Virus Mosquito Infection Are Associated with a Highly Conserved Alphavirus and Flavivirus Envelope Sequence. J. Virol.
82: 2966-2974
[Abstract]
[Full Text]
-
Arroyo, J., Miller, C., Catalan, J., Myers, G. A., Ratterree, M. S., Trent, D. W., Monath, T. P.
(2004). ChimeriVax-West Nile Virus Live-Attenuated Vaccine: Preclinical Evaluation of Safety, Immunogenicity, and Efficacy. J. Virol.
78: 12497-12507
[Abstract]
[Full Text]
-
PUGACHEV, K. V., GUIRAKHOO, F., MITCHELL, F., OCRAN, S. W., PARSONS, M., JOHNSON, B. W., KOSOY, O. L., LANCIOTTI, R. S., ROEHRIG, J. T., TRENT, D. W., MONATH, T. P.
(2004). CONSTRUCTION OF YELLOW FEVER/ST. LOUIS ENCEPHALITIS CHIMERIC VIRUS AND THE USE OF CHIMERAS AS A DIAGNOSTIC TOOL. Am J Trop Med Hyg
71: 639-645
[Abstract]
[Full Text]
-
Nickells, M., Chambers, T. J.
(2003). Neuroadapted Yellow Fever Virus 17D: Determinants in the Envelope Protein Govern Neuroinvasiveness for SCID Mice. J. Virol.
77: 12232-12242
[Abstract]
[Full Text]
-
Charlier, N., Leyssen, P., Paeshuyse, J., Drosten, C., Schmitz, H., Van Lommel, A., De Clercq, E., Neyts, J.
(2002). Infection of SCID mice with Montana Myotis leukoencephalitis virus as a model for flavivirus encephalitis. J. Gen. Virol.
83: 1887-1896
[Abstract]
[Full Text]